HU176180B - Process for preparing antigenic compositions - Google Patents

Process for preparing antigenic compositions Download PDF

Info

Publication number: HU176180B
Authority: HU; Hungary
Prior art keywords: antigenic protein; lipoid; mixing; solution; added
Prior art date: 1975-09-29

Application number

HU76WE542A

Other languages

English (en)

Hungarian (hu)

Inventor

June D Almeida

David C Edwards

Original Assignee

Wellcome Found

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1975-09-29

Filing date

1976-09-28

Publication date

1980-12-28

1976-09-28 Application filed by Wellcome Found filed Critical Wellcome Found

1980-12-28 Publication of HU176180B publication Critical patent/HU176180B/hu

Links

230000000890 antigenic effect Effects 0.000 title claims abstract description 30
239000000203 mixture Substances 0.000 title claims description 30
238000004519 manufacturing process Methods 0.000 title description 3
102000004169 proteins and genes Human genes 0.000 claims abstract description 34
108090000623 proteins and genes Proteins 0.000 claims abstract description 34
241000700605 Viruses Species 0.000 claims abstract description 17
238000002360 preparation method Methods 0.000 claims abstract description 10
239000002502 liposome Substances 0.000 claims description 44
238000000034 method Methods 0.000 claims description 23
239000000243 solution Substances 0.000 claims description 16
108091007433 antigens Proteins 0.000 claims description 14
102000036639 antigens Human genes 0.000 claims description 14
238000002156 mixing Methods 0.000 claims description 14
HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical group ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 claims description 12
239000000787 lecithin Substances 0.000 claims description 12
235000010445 lecithin Nutrition 0.000 claims description 12
IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 claims description 11
239000000427 antigen Substances 0.000 claims description 11
229940067606 lecithin Drugs 0.000 claims description 11
239000004005 microsphere Substances 0.000 claims description 11
150000002632 lipids Chemical class 0.000 claims description 10
210000004088 microvessel Anatomy 0.000 claims description 9
241000712461 unidentified influenza virus Species 0.000 claims description 8
238000000108 ultra-filtration Methods 0.000 claims description 7
239000007864 aqueous solution Substances 0.000 claims description 6
239000000463 material Substances 0.000 claims description 5
239000012736 aqueous medium Substances 0.000 claims description 4
239000002904 solvent Substances 0.000 claims description 4
229910019142 PO4 Inorganic materials 0.000 claims description 3
244000000010 microbial pathogen Species 0.000 claims description 3
NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 claims description 3
239000010452 phosphate Substances 0.000 claims description 3
238000003756 stirring Methods 0.000 claims description 3
239000003960 organic solvent Substances 0.000 claims 2
239000008366 buffered solution Substances 0.000 claims 1
238000001704 evaporation Methods 0.000 claims 1
239000012299 nitrogen atmosphere Substances 0.000 claims 1
238000000527 sonication Methods 0.000 claims 1
239000000232 Lipid Bilayer Substances 0.000 abstract description 3
244000052769 pathogen Species 0.000 abstract description 3
241000894006 Bacteria Species 0.000 abstract description 2
102000016607 Diphtheria Toxin Human genes 0.000 description 25
108010053187 Diphtheria Toxin Proteins 0.000 description 25
230000035931 haemagglutination Effects 0.000 description 15
LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 12
239000002953 phosphate buffered saline Substances 0.000 description 12
LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 11
241000699670 Mus sp. Species 0.000 description 11
FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 10
230000000694 effects Effects 0.000 description 10
241001465754 Metazoa Species 0.000 description 8
210000002966 serum Anatomy 0.000 description 8
210000004072 lung Anatomy 0.000 description 6
239000013642 negative control Substances 0.000 description 6
IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 5
238000003556 assay Methods 0.000 description 5
238000009472 formulation Methods 0.000 description 5
239000011780 sodium chloride Substances 0.000 description 5
229960005486 vaccine Drugs 0.000 description 5
230000003612 virological effect Effects 0.000 description 5
WCUXLLCKKVVCTQ-UHFFFAOYSA-M Potassium chloride Chemical compound [Cl-].[K+] WCUXLLCKKVVCTQ-UHFFFAOYSA-M 0.000 description 4
239000000654 additive Substances 0.000 description 4
RNPXCFINMKSQPQ-UHFFFAOYSA-N dicetyl hydrogen phosphate Chemical compound CCCCCCCCCCCCCCCCOP(O)(=O)OCCCCCCCCCCCCCCCC RNPXCFINMKSQPQ-UHFFFAOYSA-N 0.000 description 4
229940093541 dicetylphosphate Drugs 0.000 description 4
206010013023 diphtheria Diseases 0.000 description 4
238000002347 injection Methods 0.000 description 4
239000007924 injection Substances 0.000 description 4
241000699666 Mus <mouse, genus> Species 0.000 description 3
239000008346 aqueous phase Substances 0.000 description 3
230000015572 biosynthetic process Effects 0.000 description 3
210000004369 blood Anatomy 0.000 description 3
239000008280 blood Substances 0.000 description 3
239000006185 dispersion Substances 0.000 description 3
230000002209 hydrophobic effect Effects 0.000 description 3
230000028993 immune response Effects 0.000 description 3
230000002163 immunogen Effects 0.000 description 3
230000001681 protective effect Effects 0.000 description 3
239000000126 substance Substances 0.000 description 3
239000003053 toxin Substances 0.000 description 3
231100000765 toxin Toxicity 0.000 description 3
108700012359 toxins Proteins 0.000 description 3
241000700198 Cavia Species 0.000 description 2
241000700199 Cavia porcellus Species 0.000 description 2
101710154606 Hemagglutinin Proteins 0.000 description 2
101710093908 Outer capsid protein VP4 Proteins 0.000 description 2
101710135467 Outer capsid protein sigma-1 Proteins 0.000 description 2
241001494479 Pecora Species 0.000 description 2
101710176177 Protein A56 Proteins 0.000 description 2
CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 2
229930006000 Sucrose Natural products 0.000 description 2
230000000996 additive effect Effects 0.000 description 2
239000007853 buffer solution Substances 0.000 description 2
AIYUHDOJVYHVIT-UHFFFAOYSA-M caesium chloride Chemical compound [Cl-].[Cs+] AIYUHDOJVYHVIT-UHFFFAOYSA-M 0.000 description 2
210000004027 cell Anatomy 0.000 description 2
239000003795 chemical substances by application Substances 0.000 description 2
HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 2
239000003599 detergent Substances 0.000 description 2
238000000502 dialysis Methods 0.000 description 2
238000010790 dilution Methods 0.000 description 2
239000012895 dilution Substances 0.000 description 2
BNIILDVGGAEEIG-UHFFFAOYSA-L disodium hydrogen phosphate Chemical compound [Na+].[Na+].OP([O-])([O-])=O BNIILDVGGAEEIG-UHFFFAOYSA-L 0.000 description 2
210000003743 erythrocyte Anatomy 0.000 description 2
239000000185 hemagglutinin Substances 0.000 description 2
208000037797 influenza A Diseases 0.000 description 2
239000012528 membrane Substances 0.000 description 2
229910000402 monopotassium phosphate Inorganic materials 0.000 description 2
235000019796 monopotassium phosphate Nutrition 0.000 description 2
229910052757 nitrogen Inorganic materials 0.000 description 2
239000012071 phase Substances 0.000 description 2
PJNZPQUBCPKICU-UHFFFAOYSA-N phosphoric acid;potassium Chemical compound [K].OP(O)(O)=O PJNZPQUBCPKICU-UHFFFAOYSA-N 0.000 description 2
239000001103 potassium chloride Substances 0.000 description 2
235000011164 potassium chloride Nutrition 0.000 description 2
238000010254 subcutaneous injection Methods 0.000 description 2
239000007929 subcutaneous injection Substances 0.000 description 2
239000005720 sucrose Substances 0.000 description 2
239000000725 suspension Substances 0.000 description 2
238000004448 titration Methods 0.000 description 2
PORPENFLTBBHSG-MGBGTMOVSA-N 1,2-dihexadecanoyl-sn-glycerol-3-phosphate Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP(O)(O)=O)OC(=O)CCCCCCCCCCCCCCC PORPENFLTBBHSG-MGBGTMOVSA-N 0.000 description 1
TZCPCKNHXULUIY-RGULYWFUSA-N 1,2-distearoyl-sn-glycero-3-phosphoserine Chemical compound CCCCCCCCCCCCCCCCCC(=O)OC[C@H](COP(O)(=O)OC[C@H](N)C(O)=O)OC(=O)CCCCCCCCCCCCCCCCC TZCPCKNHXULUIY-RGULYWFUSA-N 0.000 description 1
OCKGFTQIICXDQW-ZEQRLZLVSA-N 5-[(1r)-1-hydroxy-2-[4-[(2r)-2-hydroxy-2-(4-methyl-1-oxo-3h-2-benzofuran-5-yl)ethyl]piperazin-1-yl]ethyl]-4-methyl-3h-2-benzofuran-1-one Chemical compound C1=C2C(=O)OCC2=C(C)C([C@@H](O)CN2CCN(CC2)C[C@H](O)C2=CC=C3C(=O)OCC3=C2C)=C1 OCKGFTQIICXDQW-ZEQRLZLVSA-N 0.000 description 1
241000711404 Avian avulavirus 1 Species 0.000 description 1
241000283690 Bos taurus Species 0.000 description 1
241000711573 Coronaviridae Species 0.000 description 1
241000701022 Cytomegalovirus Species 0.000 description 1
241000709661 Enterovirus Species 0.000 description 1
102000004190 Enzymes Human genes 0.000 description 1
108090000790 Enzymes Proteins 0.000 description 1
241000283073 Equus caballus Species 0.000 description 1
241000710198 Foot-and-mouth disease virus Species 0.000 description 1
ZWZWYGMENQVNFU-UHFFFAOYSA-N Glycerophosphorylserin Natural products OC(=O)C(N)COP(O)(=O)OCC(O)CO ZWZWYGMENQVNFU-UHFFFAOYSA-N 0.000 description 1
241000712079 Measles morbillivirus Species 0.000 description 1
241000711386 Mumps virus Species 0.000 description 1
108010006232 Neuraminidase Proteins 0.000 description 1
102000005348 Neuraminidase Human genes 0.000 description 1
REYJJPSVUYRZGE-UHFFFAOYSA-N Octadecylamine Chemical compound CCCCCCCCCCCCCCCCCCN REYJJPSVUYRZGE-UHFFFAOYSA-N 0.000 description 1
208000002606 Paramyxoviridae Infections Diseases 0.000 description 1
241000709664 Picornaviridae Species 0.000 description 1
208000000474 Poliomyelitis Diseases 0.000 description 1
206010037660 Pyrexia Diseases 0.000 description 1
108010067390 Viral Proteins Proteins 0.000 description 1
208000036142 Viral infection Diseases 0.000 description 1
238000004220 aggregation Methods 0.000 description 1
230000002776 aggregation Effects 0.000 description 1
125000001931 aliphatic group Chemical group 0.000 description 1
239000007900 aqueous suspension Substances 0.000 description 1
239000000872 buffer Substances 0.000 description 1
239000000969 carrier Substances 0.000 description 1
238000005119 centrifugation Methods 0.000 description 1
239000002801 charged material Substances 0.000 description 1
239000003153 chemical reaction reagent Substances 0.000 description 1
235000012000 cholesterol Nutrition 0.000 description 1
229940028617 conventional vaccine Drugs 0.000 description 1
229910001873 dinitrogen Inorganic materials 0.000 description 1
125000003438 dodecyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
229940079593 drug Drugs 0.000 description 1
239000003814 drug Substances 0.000 description 1
229940088679 drug related substance Drugs 0.000 description 1
238000002474 experimental method Methods 0.000 description 1
150000002270 gangliosides Chemical class 0.000 description 1
230000000521 hyperimmunizing effect Effects 0.000 description 1
230000001900 immune effect Effects 0.000 description 1
230000003053 immunization Effects 0.000 description 1
238000002649 immunization Methods 0.000 description 1
208000037798 influenza B Diseases 0.000 description 1
208000037799 influenza C Diseases 0.000 description 1
238000010255 intramuscular injection Methods 0.000 description 1
239000007927 intramuscular injection Substances 0.000 description 1
239000007788 liquid Substances 0.000 description 1
238000003760 magnetic stirring Methods 0.000 description 1
238000001000 micrograph Methods 0.000 description 1
125000000913 palmityl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
239000003182 parenteral nutrition solution Substances 0.000 description 1
239000002245 particle Substances 0.000 description 1
239000000546 pharmaceutical excipient Substances 0.000 description 1
150000003905 phosphatidylinositols Chemical class 0.000 description 1
239000013641 positive control Substances 0.000 description 1
239000003755 preservative agent Substances 0.000 description 1
150000003141 primary amines Chemical class 0.000 description 1
230000009290 primary effect Effects 0.000 description 1
230000009291 secondary effect Effects 0.000 description 1
239000012064 sodium phosphate buffer Substances 0.000 description 1
238000005476 soldering Methods 0.000 description 1
239000003381 stabilizer Substances 0.000 description 1
238000010186 staining Methods 0.000 description 1
238000010561 standard procedure Methods 0.000 description 1
125000004079 stearyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
239000006228 supernatant Substances 0.000 description 1
238000009210 therapy by ultrasound Methods 0.000 description 1
241001529453 unidentified herpesvirus Species 0.000 description 1
210000004291 uterus Anatomy 0.000 description 1
230000009385 viral infection Effects 0.000 description 1
238000005406 washing Methods 0.000 description 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
- A61K9/1271—Non-conventional liposomes, e.g. PEGylated liposomes or liposomes coated or grafted with polymers
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55555—Liposomes; Vesicles, e.g. nanoparticles; Spheres, e.g. nanospheres; Polymers

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Epidemiology (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
Medicinal Chemistry (AREA)
General Health & Medical Sciences (AREA)
Animal Behavior & Ethology (AREA)
Pharmacology & Pharmacy (AREA)
Immunology (AREA)
Mycology (AREA)
Microbiology (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Dispersion Chemistry (AREA)
Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Medicinal Preparation (AREA)
Preparation Of Compounds By Using Micro-Organisms (AREA)
Micro-Organisms Or Cultivation Processes Thereof (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Medicines Containing Material From Animals Or Micro-Organisms (AREA)

HU76WE542A 1975-09-29 1976-09-28 Process for preparing antigenic compositions HU176180B (en)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
GB39857/75A GB1564500A (en)	1975-09-29	1975-09-29	Biological preparations

Publications (1)

Publication Number	Publication Date
HU176180B true HU176180B (en)	1980-12-28

Family

ID=10411873

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
HU76WE542A HU176180B (en)	1975-09-29	1976-09-28	Process for preparing antigenic compositions

Country Status (15)

Country	Link
JP (1)	JPS5244228A (fr)
AU (1)	AU514848B2 (fr)
BE (1)	BE846681A (fr)
BG (1)	BG34181A3 (fr)
CA (1)	CA1079634A (fr)
DD (1)	DD127598A5 (fr)
DE (1)	DE2643641A1 (fr)
ES (1)	ES451923A1 (fr)
FR (1)	FR2325387A1 (fr)
GB (1)	GB1564500A (fr)
HU (1)	HU176180B (fr)
NL (1)	NL7610736A (fr)
PL (1)	PL103082B1 (fr)
SE (1)	SE7610708L (fr)
ZA (1)	ZA765817B (fr)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US4196191A (en)	1975-09-29	1980-04-01	Burroughs Wellcome Co.	Biological preparations
US4148876A (en)	1975-09-29	1979-04-10	Burroughs Wellcome Co.	Biological preparations
FR2442241A2 (fr) *	1978-03-20	1980-06-20	Anvar	Nouveaux composes esters de muramyl-peptide, leur preparation et les compositions pharmaceutiques les contenant, notamment sous forme de liposomes
FR2420545A1 (fr) *	1978-03-20	1979-10-19	Anvar	Nouveaux esters de l'acide n-acetyl-muramyl-aminoacyl-glutamique ou des derives de substitution de celui-ci a proprietes anti-infectieuses et/ou d'adjuvants immunologiques
GB2026340B (en) *	1978-07-03	1982-12-22	Ash P	Stabilising microvesicles
US4201767A (en) *	1978-11-08	1980-05-06	Merck & Co., Inc.	Viral liposome particle
US4199565A (en) *	1979-03-26	1980-04-22	Merck & Co., Inc.	Liposome particle containing viral or bacterial antigenic subunit
HU184141B (en) *	1979-12-27	1984-07-30	Human Oltoanyagtermelo	Adjuvant particles compositions containing said particles and biologically active substances adsorbed thereon and a process for the preparation thereof
DE3173713D1 (en) *	1980-09-05	1986-03-20	Frappier Armand Inst	Formation of an immunosome exclusively made of viral antigens reconstituted on an artificial membrane
FR2543018B1 (fr) *	1983-03-22	1985-07-26	Oreal	Procede de preparation de vesicules lipidiques par vaporisation de solvants
IT1238343B (it) *	1989-10-16	1993-07-13	Cesalpino Andrea Fond	Procedimento per la preparazione di vaccini capaci di generare non solo la risposta immune dei linfociti t helper,ma anche un'efficace risposta di linfociti t citotossici,e vaccini con queste caratteristiche
FI944052A7 (fi) *	1992-03-03	1994-09-02	Daiichi Seiyaku Co	Oraalinen rokote
US6096291A (en) *	1996-12-27	2000-08-01	Biovector Therapeutics, S.A.	Mucosal administration of substances to mammals
CN105899220B (zh) *	2013-12-19	2020-01-10	扬森疫苗与预防公司	改进的病毒体配制品

1975
- 1975-09-29 GB GB39857/75A patent/GB1564500A/en not_active Expired
1976
- 1976-09-28 PL PL1976192701A patent/PL103082B1/pl unknown
- 1976-09-28 ZA ZA00765817A patent/ZA765817B/xx unknown
- 1976-09-28 FR FR7629064A patent/FR2325387A1/fr active Granted
- 1976-09-28 AU AU18164/76A patent/AU514848B2/en not_active Expired
- 1976-09-28 HU HU76WE542A patent/HU176180B/hu unknown
- 1976-09-28 BE BE171023A patent/BE846681A/fr not_active IP Right Cessation
- 1976-09-28 JP JP51116473A patent/JPS5244228A/ja active Pending
- 1976-09-28 NL NL7610736A patent/NL7610736A/xx not_active Application Discontinuation
- 1976-09-28 ES ES451923A patent/ES451923A1/es not_active Expired
- 1976-09-28 CA CA262,165A patent/CA1079634A/fr not_active Expired
- 1976-09-28 SE SE7610708A patent/SE7610708L/ not_active Application Discontinuation
- 1976-09-28 BG BG034303A patent/BG34181A3/xx unknown
- 1976-09-28 DD DD7600195018A patent/DD127598A5/xx unknown
- 1976-09-28 DE DE19762643641 patent/DE2643641A1/de not_active Withdrawn

Also Published As

Publication number	Publication date
ES451923A1 (es)	1977-08-16
FR2325387A1 (fr)	1977-04-22
DE2643641A1 (de)	1977-04-14
PL103082B1 (pl)	1979-05-31
AU514848B2 (en)	1981-03-05
NL7610736A (nl)	1977-03-31
JPS5244228A (en)	1977-04-07
SE7610708L (sv)	1977-03-30
CA1079634A (fr)	1980-06-17
BE846681A (fr)	1977-03-28
FR2325387B1 (fr)	1980-06-27
ZA765817B (en)	1978-05-30
DD127598A5 (de)	1977-10-05
GB1564500A (en)	1980-04-10
BG34181A3 (en)	1983-07-15
AU1816476A (en)	1978-04-06

Publication	Publication Date	Title
US4196191A (en)	1980-04-01	Biological preparations
US4148876A (en)	1979-04-10	Biological preparations
JP3923518B2 (ja)	2007-06-06	ワクチン組成物用アジュバント
US6090406A (en)	2000-07-18	Potentiation of immune responses with liposomal adjuvants
CA1337332C (fr)	1995-10-17	Vaccin contre l'influenza et nouveaux adjuvants
US5916588A (en)	1999-06-29	Peptide-containing liposomes, immunogenic liposomes and methods of preparation and use
De Haan et al.	1995	Mucosal immunoadjuvant activity of liposomes: induction of systemic IgG and secretory IgA responses in mice by intranasal immunization with an influenza subunit vaccine and coadministered liposomes
JP4010462B2 (ja)	2007-11-21	インフルエンザワクチン組成物
US6261573B1 (en)	2001-07-17	Immunoadjuvants
CN107296792B (zh)	2021-07-27	囊泡及由其产生之制剂的制备方法
US5643574A (en)	1997-07-01	Protein- or peptide-cochleate vaccines and methods of immunizing using the same
JP2000513352A (ja)	2000-10-10	リポソームインフルエンザワクチンの組成物および方法
EP2058002A1 (fr)	2009-05-13	Membranes reconstituées du virus respiratoire syncytial et utilisation en tant que vaccin contre le virus respiratoire syncytial
JP2001523216A (ja)	2001-11-20	新規のアジュバント組成物と、それからなるワクチン製剤
CA1079634A (fr)	1980-06-17	Antigenes fixes a la surface externe de microvesicules
EP0356340B1 (fr)	1994-11-02	Vaccin à affinité associée
US9540420B2 (en)	2017-01-10	Mucosal vaccines
US6890540B1 (en)	2005-05-10	Vaccine formulation
US8287887B2 (en)	2012-10-16	Antigen-and-drug vehicle comprising synthetic peptide, and mucosal vaccine using the same
Gregoriadis et al.	1992	Liposomes enhance the immunogenicity of reconstituted influenza virus A/PR/8 envelopes and the formation of protective antibody by influenza virus A/Sichuan/87 (H3N2) surface antigen
Boudreault et al.	1985	Mouse response to influenza immunosomes
DE69127975T2 (de)	1998-02-12	Impfstoffe
US5985318A (en)	1999-11-16	Fusogenic liposomes that are free of active neuraminidase
PT1346727E (pt)	2010-05-21	Método para a obtenção de agregados antigénicos e a sua utilização em formulações
KR0137360B1 (ko)	1998-04-25	인플루엔자 백신과 새로운 보조제